REG - Proteome Sciences - AGM Statement

Proteome SciencesAnnouncement

16/05/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220516:nRSP5142La&default-theme=true

RNS Number : 5142L  Proteome Sciences PLC  16 May 2022

16 May 2022

 

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Annual General Meeting (AGM) Statement

 

At the Company's AGM being held today at 12.00 noon, the Chairman, Christopher
Pearce, will make the following statement:

 

"With continuous business growth and a particularly good performance in our
service business, we recorded a small profit and an adjusted EBITDA* of
£1.35m (2020: £0.72m) for the year ended 31 December 2021. We were able to
gain a record number of contracts including a substantial order in excess of
£1m. Also, our TMT revenues remained strong underlining the USP we have in
the proteomics field with these reagents.  Based on the strategic process we
ran in 2021 we decided to add a high value, high demand service to our
portfolio -single cell proteomics - and to increase our USP of proprietary
tags by developing new, innovative reagents. The progress over the last three
years has created an excellent platform for the further development of the
company. The strong order book, cash position and strategic plan provide a
basis to grow all aspects of our business in 2022. We started strategic
investments in staff and instruments in 2021 and continue to do so in 2022.
The board has an increased confidence of profits growth in 2022."

 

*  - Adjusted EBITDA is a non-GAAP company specific measure which is
considered to be a key performance indicator of the Group's financial
performance. Adjusted EBITDA is calculated as operating profit before
depreciation (including right-to-use assets amortisation), amortisation,
non-recurring costs, and employee share-based payment.

 

For further information:

 

 Proteome Sciences plc
 Dr Mariola Soehngen, Chief Executive Officer  Tel: +44 (0)20 7043 2116

 Dr Ian Pike, Chief Scientific Officer

 Allenby Capital Limited (AIM Nominated Adviser & Broker)
 John Depasquale / Jeremy Porter               Tel: +44 (0) 20 3328 5656

 

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying
and contextualising new targets and defining mechanisms of biological
activity, while analysis using Super-Depletion and TMTcalibrator™ provides
access to over 8,500 circulating plasma proteins for the discovery of
disease-related biomarkers. Targeted assay development using mass spectrometry
delivers high sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in
Frankfurt, Germany.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGMAJMFTMTBBBJT